It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Patients treated with chemotherapy plus radiotherapy had a 64% reduced likelihood of disease progression or death compared with those who underwent chemotherapy alone.
The purpose of this study was to develop and test a gene-expression profiling assay to facilitate patient selection for induction chemotherapy in the setting of LA-NPC.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Preclinical data has suggested that radiotherapy can increase sensitivity to immunotherapy and that immunotherapy can sensitize cancer cells to radiation.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
The majority of patients enrolled in this study were unable to receive cisplatin due to an ear-related comorbidity.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.